Mateo Mejia Saldarriaga, M.D.


Locations and Appointments

Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

*Indicates this doctor is no longer accepting new patients with this insurance plan.

  • HMO
  • Medicare
  • PPO
  • Blue Access
  • Blue Connection
  • EPO
  • HMO
  • Mediblue (Senior)
  • PPO
  • CBP
  • Medicaid
  • Medicare
  • Freedom
  • Liberty
  • Medicare Advantage
  • Metro/Core/Charter
  • Community Plan
  • Medicare
  • HMO
  • Medicare
Personal Statement

Early during my medical education, I was privileged to work closely with patients living with multiple myeloma. I realized early on that although tremendous progress had been made in the treatment of this blood cancer, there were still many myeloma patients whose disease progressed despite available therapies. Even now, while there have been big scientific leaps in our overall understanding of the pathophysiology behind myeloma, we still do not fully understand exactly what leads to highly aggressive forms of this disease, or why myeloma has a higher incidence in certain populations such as Latinx and African-Americans.

I envision a future in which all patients with myeloma can access highly active and effective therapies, and in which improvements in understanding the disease biology can offer those with more aggressive subtypes treatment options targeted specifically for their forms of the disease.

I am grateful to be fulfilling my dream of helping all patients affected by myeloma by providing direct, compassionate, up to date, and humanistic care, and to conduct research that will further refine the treatment of this type of cancer.

Biographical Info

Dr. Mateo Mejia is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine and an Assistant Attending Physician at NewYork-Presbyterian Hospital.

Dr. Mejia received his medical degree (M.D.) from the Universidad CES in his hometown of Medellin, Colombia, after which he completed an internal medicine residency at the Jacobi Medical Center/Albert Einstein College of Medicine in the Bronx, NY, where he also served as a Chief Resident. He completed his Hematology and Oncology fellowship at Weill Cornell Medicine/NewYork-Presbyterian Hospital and joined the Hematology and Medical Oncology Division after completing his fellowship training in 2023. During fellowship, Dr. Mejia developed his clinical experience under the mentorship of Dr. Ruben Niesvizky, while pursuing his laboratory research at Dr. Mark Bustoros’ Laboratory, being able to complete both clinical and translational research in the plasma cell malignancy field.

Dr. Mejia’s research has focused on the genomic drivers of aggressive forms of myeloma, for which he received the 2022 Conquer Cancer – American Society of Clinical Oncology (ASCO) Young Investigator Award, a prestigious honor only given to 100 of people each year. Additionally, Dr. Mejia was the recipient ofthe 2022 Charles, Lillian and Betty Neuwirth Foundation Fellowship in Oncology award for his project “Genomic Landscape of Multiple Myeloma with Extramedullary Disease”. Dr. Mejia’s research also investigates the connectionof race, ethnicity and myeloma, how myeloma escapes the surveillance of the immune system, as well as how genetic information can be used to develop novel approaches to treat myeloma.

Board Certifications
American Board of Internal Medicine
  • M.D.
    Institute of Health Sciences, CES, Faculty of Medicine (Colombia)
  • Assistant Attending Physician
    NewYork-Presbyterian Hospital
  • Assistant Professor of Medicine
    Weill Cornell Medical College, Cornell University

Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

No External Relationships Reported